ShIZOFRENIYa I UPOTREBLENIE PSIKhOAKTIVNYKh VEShchESTV: PODKhODY K DIAGNOSTIKE I VYBORU ANTIPSIKhOTIChESKOY TERAPII
- Authors: Ivanov M.V1, Shipilin M.Y.1, Yanushko M.G1
-
Affiliations:
- Issue: No 3s (2013)
- Pages: 34-38
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280315
- ID: 280315
Cite item
Open Access
Access granted
Abstract
The use of amphetamine/methamphetamine-type stimulants occurs widely in the population of schizophrenic patients. The article presents an analysis of the pathogenesis, clinical features, and the comparative effectiveness of different antipsychotic treatments of psychosis induced by psychoactive substances in schizophrenic patients. The data on the spectrum of cognitive impairments in schizophrenic patients with substance use compared to patients with schizophrenia without a history of substance use are presented. The data obtained provide more evidence of the similarity of the neurobiological mechanisms of schizophrenia and the effects of use of psychoactive substances. Management of mental disorders induced by amphetamine/methamphetamine-type stimulants remains underinvestigated.
Full Text
References
- Boileau I, Payer D, Houle S, Behzadi A, Pablo Rusjan PM, et al. Higher binding of the dopamine D3 receptor-preferring ligand[11C]-(+)-PHNO in Methamphetamine Polydrug Users: A Positron Emission Tomography Study. J Neurosci 2012;32(4):1353-59. doi:10.1523/ JNEUROSCI.4371-11.2012.
- Chambers RA, Krystal JH, Self DW. A neuro-biological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50(2): 71 -83. doi: 10.1016/S0006-3223(01 ) 01134-39.
- Connell PH. Amphetamine Psychosis. Maudsley Monograph No. 5. London: Oxford University Press, 1958.
- Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, et al. Clinical course and outcomes of meth-amphetaminedependent adults with psychosis. J Subst Abuse Treat 2008;35(4):445-50.
- Grant KM, Levan TD, Wells SM, et al. Methamphetamine-Associated Psychosis. J Neuroimmune Pharmacol 2011;7(1):113-39.
- Kapur S, Murray RM, Zanelli J, et al. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry 2010;167(1):78-85.
- Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4(5):231-44.
- Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000;31(2-3):371-84.
- Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai 2005;88(Suppl 3):S43-52.
- Murthy P, Chand P. Treatment of dual diagnosis disorders. Curr Opin Psychiatry.2012;25(3):194-200.
- Rockville MD. NSDUH Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication № SMA 09-4434). 2009: 242-2437.
- Potvin S, Stip E, Lipp O, Roy MA, Demers MF, Bouchard RH, Gendron A. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. Am J Drug Alcohol Abuse 2008;34(1):75-82.
- Potvin S, Stip E, Roy JY. Schizophrenia and addiction: An evaluation of the self-medication hypothesis. Encephale. 2003;29(3 Pt 1): 193-203.
- Salo R, Ravizza S, Fassbender C. Overlapping Cognitive Patterns in Schizophrenia and Methamphetamine Dependence. Cogn Behav Neurol 2011;24(4):187-93.
Supplementary files
